Outcomes of an HCV elimination program targeting the Viennese MSM population
Tóm tắt
Recent reports suggest an increasing incidence of hepatitis C virus (HCV) infections among MSM (men-who-have-sex-with-men). Early treatment with direct-acting antivirals (DAAs) achieves high cure rates and prevents further HCV transmission. We offered barrier-free HCV screening in the Viennese MSM population and immediate access to DAA treatment. In collaboration with gay health specialists, we screened for HCV seropositivity in Viennese MSM between 2019 and 2020. Barrier-free HCV-RNA-PCR tests, transient elastography (TE) and immediate access to DAA treatment were offered. A total of 310 HCV-seropositive patients were identified. Of those, 145 could be contacted and 109 attended their appointment at our clinic. HIV-coinfection was highly prevalent in our cohort (n = 86/145; 78.9%), while pre-exposure prophylaxis (PrEP) was taken by 21.7% (n = 5/23) of non-HIV patients. Sexual risk behavior and (history of) intravenous drug use was reported by 32.1% and 13.8% of patients, respectively. Most MSM had already achieved sustained virological response (SVR) to previous antiviral treatment (n = 72, 66.1%) or experienced spontaneous clearance (n = 10, 9.2%). Advanced fibrosis was only detected in 3/109 (2.8%) patients. 30 MSM tested positive for HCV-RNA and DAA treatment was initiated in 29 patients – all achieved SVR. A targeted HCV test-and-treat program revealed a high prevalence of HCV seropositivity among Viennese MSM, potentially associated with high-risk sexual behavior and drug use. Early DAA treatment seems warranted in viremic HCV-MSM as SVR was 100%, which in turn prevents further HCV transmission.
Tài liệu tham khảo
Chromy D, Mandorfer M, Bucsics T, et al. High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients. United European Gastroenterol J. 2019;7(4):507–16.
Schmidbauer C, Chromy D, Schmidbauer V, et al. Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. Liver Int. 2020;40(4):787–96.
Pradat P, Huleux T, Raffi F, et al. Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV. AIDS. 2018;32(8):1077–82.
Smit C, Boyd A, Rijnders BJA, et al. HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study. Lancet HIV. 2021;8(2):e96–e105.
Cotte L, Cua E, Reynes J, et al. Hepatitis C virus incidence in HIV-infected and in preexposure prophylaxis (PrEP)-using men having sex with men. Liver Int. 2018;38(10):1736–40.
Jin F, Dore GJ, Matthews G, et al. Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(1):39–56.
Chromy D, Schmidt R, Mandorfer M, et al. Hepatitis C virus RNA is commonly detectable in rectal and nasal fluids of patients with high viremia. Clin Infect Dis. 2020;71(5):1292–9.
Palaniswami PM, El Sayed A, Asriel B, Carollo JR, Fierer DS. Ledipasvir and sofosbuvir in the treatment of early hepatitis C virus infection in HIV-infected men. Open Forum Infect Dis. 2018;5(10):ofy238.
Popping S, Hullegie SJ, Boerekamps A, et al. Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men. PLoS One. 2019;14(1):e210179.
Salazar-Vizcaya L, Kouyos RD, Fehr J, et al. On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: a mathematical modelling study. J Viral Hepat. 2018;25(1):10–8.
EASL. EASL recommendations on treatment of hepatitis C: final update of the series(☆). J Hepatol. 2020;73(5):1170–218.
Steininger L, Chromy D, Bauer D, et al. Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence. Wien Klin Wochenschr. 2020;133(9-10):452–60.
EASL. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511.
Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343–50.
Mandorfer M, Schwabl P, Steiner S, Reiberger T, Peck-Radosavljevic M. Advances in the management of HIV/HCV coinfection. Hepatol Int. 2016;10(3):424–35.
World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. Geneva: World Health Organization; 2016.
Mandorfer M, Schwabl P, Steiner S, et al. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100 % of HIV/hepatitis C virus-coinfected patients with advanced liver disease. Aids. 2016;30(7):1039–47.
Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV. Management of acute HCV infection in the era of direct-acting antiviral therapy. Nat Rev Gastroenterol Hepatol. 2018;15(7):412–24.
Chromy D, Schwabl P, Bucsics T, et al. Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients. Wien Klin Wochenschr. 2018;130(3-4):105–14.
Mandorfer M, Kozbial K, Freissmuth C, et al. Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. Aliment Pharmacol Ther. 2015;42(6):707–18.